Oncolytics Biotech(R) Inc. Enters into First-in-Class Collaboration with Myeloma UK and Celgene Using REOLYSIN(R) in Combination with Imnovid(R) or Revlimid(R) in Patients with Myeloma

CALGARY, March 16, 2017 -- (Healthcare Sales & Marketing Network) - Oncolytics Biotech® Inc. (Oncolytics or the Company) (ONC.TO) (ONCYF) today announced that cancer charity Myeloma UK launched MUK eleven, a first-of-its-kind immunotherapy trial that ... Biopharmaceuticals, Oncology Oncolytics Biotech, REOLYSIN, pelareorep, pomalidomide, Revlimid, myeloma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news